Added to YB: 2026-02-20
Pitch date: 2026-02-17
VRTX [bullish]
Vertex Pharmaceuticals Incorporated
-0.93%
current return
Author Info
No bio for this author
Company Info
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Market Cap
$119.5B
Pitch Price
$473.68
Price Target
514.32 (+10%)
Dividend
N/A
EV/EBITDA
21.37
P/E
30.70
EV/Sales
9.10
Sector
Biotechnology
Category
growth
Top Picks 2026: A Map of Opportunities in Transformational Markets | Vertex Pharmaceuticals Inc. (VRTX) — CRISPR Gene Editing Reaches Market
VRTX: First approved CRISPR therapy (exa-cel/CASGEVY) for sickle cell disease & beta-thalassemia. 32k eligible US patients, $3-5B+ peak sales est. 2026 catalysts: commercialization ramp, pediatric expansion (5-11yr), reimbursement deals. Strong balance sheet, net cash. Price target $514 from $474 = 8.5% return. Consensus: Strong Buy.
Read full article (1 min)